Monday, 14 September 2026European Markets

CONTEXTVISION And ESSILORLUXOTTICA Have A High Dividend Yield And Return On Equity In The Healthcare Sector.

Loading stream...

(vianews) - contextvision (contx.ol) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.

financial asset price forward dividend yield return on equity
contextvision (contx.ol) kr8.00 3.75% 61.1%
essilorluxottica (el.pa) €173.80 1.83% 6.16%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. contextvision (contx.ol)

3.75% forward dividend yield and 61.1% return on equity

contextvision ab (publ), a medical technology software company, provides image analysis and imaging for medical systems in asia, europe, and the united states. the company offers image enhancement software for 2d/3d/4d ultrasound, radiography, magnetic resonance imaging (mri), and veterinary. its products include rivent that offers unparalleled image quality for various types of ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; rivent mobile, an enhancing ultrasound image for the handheld ultrasound devices using mobile phones and tablets; and rivent 3d, an image enhancement product for 3d ultrasound. the company also provides altumira/altumira plus, a platform for digital radiography; and orthopedic package for orthopedic imaging. in addition, it offers gopview mri2plus, an image enhancement solution for mri. the company was founded in 1983 and is headquartered in stockholm, sweden.

earnings per share

as for profitability, contextvision has a trailing twelve months eps of kr0.45.

pe ratio

contextvision has a trailing twelve months price to earnings ratio of 17.78. meaning, the purchaser of the share is investing kr17.78 for every norwegian krone of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 61.1%.

earnings before interest, taxes, depreciation, and amortization

contextvision's ebitda is 49.39.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, contextvision's stock is considered to be oversold (<=20).

volume

today's last reported volume for contextvision is 56531 which is 32.58% above its average volume of 42636.

more news about contextvision.

2. essilorluxottica (el.pa)

1.83% forward dividend yield and 6.16% return on equity

essilorluxottica société anonyme engages in design, manufacture, and distribution of ophthalmic lenses, frames, and sunglasses in europe, middle east, africa, latin america, asia-pacific, and north america. it operates through professional solutions and direct to consumer segments. the company offers lens under the crizal, essilor, eyezen, stellest, xperio, optifog, satisloh, barberini, shamir, nikon, kodak lens, oakley, optifog, ray-ban, transitions, vailux, and xperio brands. it also provides eyewear products under the ray-ban, oakley, persol, oliver peoples, alain mikli, costa del mar, native eyewear, luxottica, sferoflex, heritage, sensaya, miki ninn, dbyd, unofficial and seen, arnette, vogue eyewear, bolon, molsion, and ossé, as well as other licensed brands. in addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. it wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of physical stores or its online channels. the company was formerly known as essilor international société anonyme and changed its name to essilorluxottica société anonyme in october 2018. essilorluxottica société anonyme was founded in 1849 and is headquartered in paris, france.

earnings per share

as for profitability, essilorluxottica has a trailing twelve months eps of €4.84.

pe ratio

essilorluxottica has a trailing twelve months price to earnings ratio of 35.91. meaning, the purchaser of the share is investing €35.91 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.16%.

volatility

essilorluxottica's last week, last month's, and last quarter's current intraday variation average was a negative 0.81%, a positive 0.11%, and a positive 1.08%.

essilorluxottica's highest amplitude of average volatility was 1.50% (last week), 1.20% (last month), and 1.08% (last quarter).

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, essilorluxottica's stock is considered to be overbought (>=80).

volume

today's last reported volume for essilorluxottica is 141118 which is 71.51% below its average volume of 495338.

more news about essilorluxottica.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Keeps Flowing as Enterprise Adoption and Government Contracts Validate the Bet
A late-August surge of nine-figure funding rounds (Socure, Stability AI, Generalist AI, Gatik, Regent Craft, Emerald AI, Owner) shows venture capital still pouring into AI infrastructure, identity/fintech, and autonomy, even as public-market sentiment stays jumpy — Palantir's stock fell 6% the same week it landed the Army's TITAN contract. UiPath's raised guidance and strong Q2 results, alongside efficiency breakthroughs like Multiverse Computing's model compression, point to real enterprise monetization catching up to the funding hype.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts record the same attribute (net_income) for JPMorgan Chase & Co. in the identical fiscal period (Q1 2026) and observation date (2026-03-31), but report values that differ by approximately 1 billion times: $16,494,000,000 vs $16.49. These cannot both be true simultaneously. The discrepancy suggests either a unit mismatch (e.g., one is total net income, the other earnings per share mislabeled as net_income), a decimal point error, or data entry corruption. For the same entity, attribute, and time period, only one value can be correct.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,285 source documents archived
Query this data → isubstrate.com